2011-2012

This page in English

2012

Treat-to-target in systemic lupus erythematosus: where are we today?
Mosca M, Boumpas D, Bruce I, Cervera R, Czirjak L, Dörner T, et al
Clin. Exp. Rheumatol. ;30(4 Suppl 73):S112-5

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.
Kastbom A, Cöster L, Arlestig L, Chatzidionysiou A, van Vollenhoven R, Padyukov L, et al
BMJ Open 2012 ;2(5):

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
Weinblatt M, Fleischmann R, Huizinga T, Emery P, Pope J, Massarotti E, et al
Rheumatology (Oxford) 2012 Dec;51(12):2204-14

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.
Simard J, Neovius M, Askling J,
Arthritis Rheum. 2012 Nov;64(11):3502-10

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven R, Fleischmann R, Cohen S, Lee E, García Meijide J, Wagner S, et al
N. Engl. J. Med. 2012 Aug;367(6):508-19

Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, et al
J. Rheumatol. 2012 Oct;39(10):2008-11

Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.
Arkema E, van Vollenhoven R, Askling J,
Ann. Rheum. Dis. 2012 Nov;71(11):1865-7

Pregnancy-associated inflammatory markers are elevated in pregnant women with systemic lupus erythematosus.
Björkander S, Bremme K, Persson J, van Vollenhoven R, Sverremark-Ekström E, Holmlund U
Cytokine 2012 Aug;59(2):392-9

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
Keystone E, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, et al
Rheumatology (Oxford) 2012 Sep;51(9):1628-38

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Petri M, Orbai A, Alarcón G, Gordon C, Merrill J, Fortin P, et al
Arthritis Rheum. 2012 Aug;64(8):2677-86

Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis.
Mullazehi M, Wick M, Klareskog L, van Vollenhoven R, Rönnelid J
Arthritis Res. Ther. 2012 May;14(3):R100

Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.
Arkema E, Neovius M, Joelsson J, Simard J, van Vollenhoven R
Ann. Rheum. Dis. 2012 Jul;71(7):1203-6

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.
Hanly J, Urowitz M, Su L, Gordon C, Bae S, Sanchez-Guerrero J, et al
Ann. Rheum. Dis. 2012 Sep;71(9):1502-9

[Rheumatologic research with animal experiments is important for our patients].
Rudin A, Sturfelt G, Carlsten H, Hafström I, Lundberg I, Klareskog L, et al
Lakartidningen ;109(1-2):40

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven R, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson I, et al
Lancet 2012 May;379(9827):1712-20

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
van Vollenhoven R, Petri M, Cervera R, Roth D, Ji B, Kleoudis C, et al
Ann. Rheum. Dis. 2012 Aug;71(8):1343-9

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
Bengtsson A, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven R, Axelsson B, et al
Arthritis Rheum. 2012 May;64(5):1579-88

Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis.
Dervieux T, Wessels J, Kremer J, Padyukov L, Seddighzadeh M, Saevarsdottir S, et al
Pharmacogenet. Genomics 2012 Jan;22(1):1-9

Rituximab - shadow, illusion or light?
van Vollenhoven R
Autoimmun Rev 2012 Jun;11(8):563-7

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak P, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven R, Stohl W, et al
Ann. Rheum. Dis. 2012 Mar;71(3):351-7

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, et al
Ann. Rheum. Dis. 2012 Mar;71(3):374-7

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
Urowitz M, Gladman D, Ibañez D, Fortin P, Bae S, Gordon C, et al
Arthritis Care Res (Hoboken) 2012 Jan;64(1):132-7

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.
Rezaei H, Saevarsdottir S, Forslind K, Albertsson K, Wallin H, Bratt J, et al
Ann. Rheum. Dis. 2012 Feb;71(2):186-91

Biologicals for the treatment of systemic lupus erythematosus?
Gunnarsson I, van Vollenhoven R
Ann. Med. 2012 May;44(3):225-32

2011

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace D, Tegzová D, et al
Arthritis Rheum. 2011 Dec;63(12):3918-30

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.
Hanly J, Urowitz M, Su L, Bae S, Gordon C, Clarke A, et al
Ann. Rheum. Dis. 2011 Oct;70(10):1726-32

"Introduction"
van Vollenhoven R, Severens J
Clin. Rheumatol. 2011 Jan;30(1):S1-S2

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al
Ann. Rheum. Dis. 2011 Nov;70(11):1895-904

Integrated safety in tocilizumab clinical trials.
Schiff M, Kremer J, Jahreis A, Vernon E, Isaacs J, van Vollenhoven R
Arthritis Res. Ther. 2011 ;13(5):R141

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, et al
Ann. Rheum. Dis. 2011 Sep;70(9):1575-80

Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.
Neovius M, Simard J, Klareskog L, Askling J,
Ann. Rheum. Dis. 2011 Aug;70(8):1407-14

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
van Vollenhoven R, Kinnman N, Vincent E, Wax S, Bathon J
Arthritis Rheum. 2011 Jul;63(7):1782-92

Decreased live births in women with systemic lupus erythematosus.
Vinet E, Clarke A, Gordon C, Urowitz M, Hanly J, Pineau C, et al
Arthritis Care Res (Hoboken) 2011 Jul;63(7):1068-72

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
Strand V, Smolen J, van Vollenhoven R, Mease P, Burmester G, Hiepe F, et al
Ann. Rheum. Dis. 2011 Jun;70(6):996-1002

How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?
Neovius M, Simard J, Askling J,
Ann. Rheum. Dis. 2011 Jun;70(6):1010-5

Unresolved issues in biologic therapy for rheumatoid arthritis.
van Vollenhoven R
Nat Rev Rheumatol 2011 Apr;7(4):205-15

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
Buch M, Smolen J, Betteridge N, Breedveld F, Burmester G, Dörner T, et al
Ann. Rheum. Dis. 2011 Jun;70(6):909-20

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
Buch M, Smolen J, Betteridge N, Breedveld F, Burmester G, Dörner T, et al
Ann. Rheum. Dis. 2011 Jun;70(6):909-20

Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis.
Fisher B, Plant D, Brode M, van Vollenhoven R, Mathsson L, Symmons D, et al
Ann. Rheum. Dis. 2011 Jun;70(6):1095-8

Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity.
Ippolito A, Wallace D, Gladman D, Fortin P, Urowitz M, Werth V, et al
Lupus 2011 Mar;20(3):250-5

More or less rituximab? Biology and clinic, regulators and researchers.
van Vollenhoven R
Arthritis Rheum. 2011 Mar;63(3):594-6

SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus.
Hanly J, Urowitz M, Jackson D, Bae S, Gordon C, Wallace D, et al
Ann. Rheum. Dis. 2011 Jun;70(6):961-7

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P, Simard J, Neovius M, Askling J,
Arthritis Rheum. 2011 Jul;63(7):1812-22

When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Chatzidionysiou K, van Vollenhoven R
J. Intern. Med. 2011 Jun;269(6):614-25

Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis.
Alemo Munters L, van Vollenhoven R, Alexanderson H
ISRN Rheumatol 2011 ;2011():463124

Observational studies: a valuable source for data on the true value of RA therapies.
van Vollenhoven R, Severens J
Clin. Rheumatol. 2011 Mar;30 Suppl 1():S19-24

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson I, et al
Ann. Rheum. Dis. 2011 Mar;70(3):469-75

Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
Neovius M, Simard J, Askling J,
Ann. Rheum. Dis. 2011 Apr;70(4):624-9

International consensus for a definition of disease flare in lupus.
Ruperto N, Hanrahan L, Alarcón G, Belmont H, Brey R, Brunetta P, et al
Lupus 2011 Apr;20(5):453-62

Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard J, Arkema E, Sundström A, Geborek P, Saxne T, Baecklund E, et al
Rheumatology (Oxford) 2011 Jan;50(1):204-13

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.
Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, et al
Scand. J. Rheumatol. 2011 Jan;40(1):8-15

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Tak P, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven R, Stohl W, et al
Ann. Rheum. Dis. 2011 Jan;70(1):39-46

American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
van Vollenhoven R, Felson D, Strand V, Weinblatt M, Luijtens K, Keystone E
Arthritis Care Res (Hoboken) 2011 Jan;63(1):128-34

Delays in assessment of patients with rheumatoid arthritis: variations across Europe.
Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H, et al
Ann. Rheum. Dis. 2011 10;70(10):1822-5

InflammationReumatologi